Spruce Biosciences
Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders
Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders
Spruce Biosciences is a clinical stage biopharmaceutical company founded in 2014. The company's mission is focused on advancing treatments for Congenital Adrenal Hyperplasia (CAH) and other rare endocrine disorders. With a slogan of "Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders", Spruce Biosciences operates within the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. The company is headquartered in the United States. It recently received a significant $53.60M Post-IPO Equity investment in 9th February 2023 from a consortium of investors including Novo Holdings, 5AM Ventures, Abingworth, HealthCap, RiverVest, Rock Springs Capital, and Armistice Capital. With this backing, Spruce Biosciences is well-positioned to continue its advancements in developing novel therapies for rare diseases affecting the endocrine system.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $53.60M | 7 |
|
09 Feb 2023 |
| Series B | $88.00M | 3 |
|
20 Feb 2020 |
| Series A | $20.00M | - | 02 Jan 2016 |
We care about your data, and we'd love to use cookies make your experience better.
